Drug Profile
Research programme: influenza monoclonal antibodies - Celltrion
Alternative Names: CT-P22; CT-P23; FirivumabLatest Information Update: 27 Oct 2021
Price :
$50
*
At a glance
- Originator Celltrion
- Class Monoclonal antibodies
- Mechanism of Action Influenza virus fusion inhibitors; Influenza virus haemagglutinin glycoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype(Prevention) in South Korea (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in South Korea (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in South Korea (Parenteral)